Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26020287 | 0.91 | HSD17B10 (0.34) | HSD17B10CYP1A2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL26412339 | 0.90 | HSD17B10 (0.34) | HSD17B10CYP1A2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL26020502 | 0.88 | CYP1A2 (0.34) | HSD17B10CYP1A2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL26412453 | 0.85 | CYP1A2 (0.33) | HSD17B10CYP1A2CYP2C19NPC1POLB | |
| SCHEMBL26412175 | 0.85 | ALDH1A1 (0.32) | HSD17B10CYP1A2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL25877376 | 0.85 | — | — | |
| SCHEMBL26020428 | 0.85 | — | — | |
| SCHEMBL25877378 | 0.85 | — | — | |
| SCHEMBL26412178 | 0.84 | APP (0.30) | APPMAPT | |
| SCHEMBL25934603 | 0.81 | PLA2G2A (0.38) | HSD17B10KDM4EALDH1A1SMN1; SMN2PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265105-A1 | MACROCYCLIC 7-PYRAZOL-5-YL-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-24 | — | — | US | disclosed |
| US-20230250109-A1 | MACROCYCLIC ETHER CONTAINING INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230130109-A1 | MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265105-A1 | MACROCYCLIC 7-PYRAZOL-5-YL-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | MCL1, BAK1, API5 | HSD17B10 4230/4885CYP1A2 3775/4885CYP2C19 4083/4885 |
| US-20230250109-A1 | MACROCYCLIC ETHER CONTAINING INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | MCL1, BAK1, BCL2L1 | HSD17B10 3605/4885CYP1A2 3285/4885CYP2C19 3880/4885 |
| US-20230130109-A1 | MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | MCL1, BCL2L1, BAK1 | HSD17B10 3902/4885CYP1A2 3669/4885CYP2C19 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.